| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC11589 | dBRD9 Featured | dBRD9 is a PROTAC that bridge the BRD9 bromodomain and the cereblon E3 ubiquitin ligase complex. |
|
| DC23976 | DC_517 | DC_05 is a potent, selective, non-nucleoside DNA methyltransferase DNMT1 inhibitor with IC50 of 1.7 uM, displays significant selectivity toward other AdoMet-dependent protein methyltransferases. |
|
| DC23977 | DC-05 Featured | DC-05 is a selective, non-nucleoside DNA methyltransferase DNMT1 inhibitor with IC50 of 10.3 uM, displays 3.6-fold selectivity over PRMT1 and >15-fold over DNMT3A, DNMT3B, G9a, SUV39H1, MLL1, SET7/9.. |
|
| DC20945 | DC_AC50 Featured | DC_AC50 (DCAC50) is a small molecule that inhibits the human copper chaperones Atox1 and CCS (Kd=6.8 and 8.2 uM), blocks copper trafficking and significantly attenuates cancer cell proliferation. |
|
| DC12361 | DC1 | DC1, an analogue of the minor groove-binding DNA alkylator CC-1065, is an antibody conjugate of cytotoxic DNA alkylators for the targeted treatment of cancer. |
|
| DC12055 | DC1-SMe | DC1-Sme is an antibody conjugate of phosphate prodrug of cytotoxic DNA alkylators for the targeted treatment of cancer. |
|
| DC5041 | DCC-2036 (Rebastinib) Featured | DCC-2036 is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) with IC50 of 0.8 nM and 4 nM, also inhibits SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit. Phase 1/2. |
|
| DC20175 | Ripretinib (DCC-2618) Featured | DCC-2618 is an orally bioavailable switch pocket control inhibitor of wild-type and mutated forms of the tumor-associated antigens (TAA) mast/stem cell factor receptor (SCFR) KIT and PDGFR-alpha, with IC50 values of 4 nM, 8 nM, 18 nM, 5 nM and 14 nM. |
|
| DC24137 | DCVC | DCVC (S-(1,2-dichlorovinyl)-L-cysteine) is an active metabolite of trichloroethylene. |
|
| DC12593 | DD-03-171 | DD-03-171 is a small molecule, CGI1746-based BTK degrader (PROTAC, biochemical IC50=5.1 nM) that efficiently degrade C481S-BTK, exhibits enhanced anti-proliferative effects on mantle cell lymphoma (MCL) cells in vitro by degrading BTK, IKFZ1 and IKFZ3. |
|
| DC20947 | DDD 85646 Featured | DDD 85646 is a potent, specific, dual N-Myristoyltransferase NMT1/NMT2 inhibitor with IC50 of 17 nM/22 nM respectively. |
|
| DC10413 | DDP-38003 dihydrochloride | DDP-38003 dihydrochloride is an novel, orally available inhibitor of histone lysine-specific demethylase 1A (KDM1A/LSD1) with an IC50 of 84 nM. |
|
| DC10996 | DDR inhibitor X Featured | DDR inhibitor X is a potent discoidin domain receptor (DDR) inhibitor with IC50 of 3.3 nM for DDR2, and shows 53% inhibition on DDR1 at 1.5 nM.. |
|
| DC12521 | DDR1 inhibitor 2.45 | DDR1 inhibitor 2.45 (Compound 2.45) is a novel potent, selective, bioavailable Discoidin Domain Receptor 1 (DDR1) inhibitor with IC50 of 29 nM, displays 64-fold selectivity over DDR2 in biochemical assays. |
|
| DC23844 | DDR1 inhibitor 7rh | DDR1 inhibitor 7rh is a potent, selective, ATP-competitive, orally available Discoidin domain receptor 1 (DDR1) inhibitor with IC50 of 6.8 nM in cell-free kinase assays. |
|
| DC23857 | DDR2-IN-5 | DDR2-IN-5 is a potent, dual DDR2/SRC inhibitor with IC50 of 56/12 nM, potently suppresses DDR2 mutated cell lines HCC-366 and NCI-H2286 with IC50 of 0.44 uM and 0.29 uM.. |
|
| DC12560 | DDR-TRK-1 | DDR-TRK-1 (DDR1 inhibitor 6j) is a potent, selective selective DDR1 inhibitor with IC50 of 9.4 nM, also potently inhibits TRK family with IC50 of 18-100 nM. |
|
| DC10111 | Debio 0617B | Debio 0617B has been developed as a first-in-class kinase inhibitor with a unique profile targeting phospho-STAT3 (pSTAT3) and/or pSTAT5 in tumors through combined inhibition of JAK, SRC, ABL, and class III/V receptor tyrosine kinases (RTK). |
|
| DC4193 | Decitabine Featured | Decitabine is a potent inhibitor of DNA methylation with IC50 of 438 nM and 4.38 nM in HL-60 and KG1a cells, respectively. |
|
| DC23727 | Dehydromutactin | Dehydromutactin is a small molecule inhibitor of RNA-binding protein Hu protein R (HuR) that interferes the HuR homodimerization with Kd of 40 nM. |
|
| DC12073 | Dehydronitrosonisoldipine | Dehydronitrosonisoldipine is a calcium channel antagonist. |
|
| DC20116 | Delafloxacin meglumine (ABT492 meglumine; RX-3341 meglumine; WQ-3034 meglumine) Featured | Delafloxacin meglumine (ABT492 meglumine; RX-3341 meglumine; WQ-3034 meglumine) is a broad-spectrum fluoroquinolone antibiotic. Delafloxacin has a broad spectrum of activity that includes drug-resistant Staphylococcus aureus, Streptococcus pneumoniae, and |
|
| DC11352 | Delavirdine (mesylate) | Delavirdine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that selectively inhibits HIV-1 reverse transcriptase over DNA polymerase α and δ in vitro (IC50s = 0.26, 440, and >550 μM, respectively). |
|
| DC8897 | Delavirdine | Delavirdine(U 90152) is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI). |
|
| DC20772 | Deleobuvir | Deleobuvir (BI-207127, BI207127) is a potent, selective HCV NS5B polymerase inhibitor with IC50 of 50 nM against GT-1 HCV polymerase activity. |
|
| DC11890 | Delgocitinib Featured | Delgocitinib (JTE-052, LEO 124249) is a potent, selective, orally active, pan-JAK inhibitor with IC50 of 2.8, 2.6, 13 and 58 nM for JAK1,2,3 and Tyk2, respectively. |
|
| DC8205 | Deltarasin Featured | Deltarasin is a novel and small molecule inhibitor which can inhibit the KRAS-PDEδ interaction(Kd= 41 nM. binding to PDEδ) and impairs oncogenic KRAS signalling. |
|
| DC20948 | Deltasonamide 2 | Deltasonamide 2 (Deltasonamide-2) is a novel small molecule inhibitor of PDE6δ/KRas interaction with Kd of 385 pM. |
|
| DC12287 | delta-Valerobetaine Featured | Delta-Valerobetaine is a precursor of trimethylamine N-oxide (TMAO). |
|
| DC20949 | Deltazinone 1 | Deltazinone 1 (Deltazinone1) is a novel highly selective PDEδ inhibitor that inhibits PDEδ/Ras interaction with Kd of 8±4 nM. |
|
